CNL, Canada's premier nuclear science facility, will conduct preclinical studies combining alpha-particle radiotherapy Actinium ... using Ac-225 have shown great promise in cancer treatment.

With multiple clinical trials underway and being planned across the AML treatment settings ... Actimab-A is Actinium's lead radiotherapy that delivers Actinium-225, a potent alpha-emitter ...

A breakthrough in cancer treatment may soon change how some of the most aggressive tumors are managed. A small, ...

Bayer has launched a first-in-human clinical trial for 225Ac-GPC3 (BAY 3547926), a novel targeted alpha radiopharmaceutical ...

Lutetium-177 and their growing capabilities for the production of Actinium-225, ITM is a valued partner as we progress our pipeline of clinical and discovery programs to meet the needs of cancer ...

NEW YORK, March 24, 2025 /PRNewswire/ -- Actinium Pharmaceuticals ... Targeted radiotherapies using Ac-225 have shown great promise in the treatment of cancer. The radioisotope releases powerful ...

“This agreement strengthens our ongoing collaboration with Alpha-9 and reaffirms our mission to supply Actinium-225 to companies pioneering ... to meaningfully improve the treatment of people living ...